Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Early Breast Cancer
Interventions: DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Taxane|DRUG: Letrozole|DRUG: Abemaciclib|DRUG: LHRH Analogue
Sponsor: Spanish Breast Cancer Research Group
Collaborators: Eli Lilly and Company